ML30098 UK Breast Cancer Productivity and Utility Study
Research type
Research Study
Full title
UK HER2 POSITIVE BREAST CANCER PRODUCTIVITY & UTILITY STUDY
IRAS ID
212432
Contact name
Mark Verrill
Contact email
Sponsor organisation
Roche Products Ltd
Duration of Study in the UK
0 years, 4 months, 20 days
Research summary
This is an observational study examining the ability to work, daily activities and health related quality of life of people treated for breast cancer. Three groups of patients will be studied; (1) on chemotherapy (including anti HER-2 drugs) for primary (early) breast cancer (eBC), (2) completed chemotherapy for eBC in follow up and (3) receiving treatment for secondary (metastatic) breast cancer. 300 trial subjects will be recruited from approximately 15 breast cancer clinics in the UK.
The aim of the study is to understand the impact on ability to work, daily activities and quality of life of women (and men) at various stages of the disease and the impact of their treatments.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
16/EE/0429
Date of REC Opinion
4 Nov 2016
REC opinion
Further Information Favourable Opinion